These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 18243703)
1. Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity. Onodera H; Kaneko M; Takahashi Y; Uochi Y; Funahashi J; Nakashima T; Soga S; Suzuki M; Ikeda S; Yamashita Y; Rahayu ES; Kanda Y; Ichimura M Bioorg Med Chem Lett; 2008 Mar; 18(5):1588-91. PubMed ID: 18243703 [TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of macbecin as an Hsp90 inhibitor. Martin CJ; Gaisser S; Challis IR; Carletti I; Wilkinson B; Gregory M; Prodromou C; Roe SM; Pearl LH; Boyd SM; Zhang MQ J Med Chem; 2008 May; 51(9):2853-7. PubMed ID: 18357975 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and anticancer activity of geldanamycin derivatives derived from biosynthetically generated metabolites. Lee K; Ryu JS; Jin Y; Kim W; Kaur N; Chung SJ; Jeon YJ; Park JT; Bang JS; Lee HS; Kim TY; Lee JJ; Hong YS Org Biomol Chem; 2008 Jan; 6(2):340-8. PubMed ID: 18175003 [TBL] [Abstract][Full Text] [Related]
4. Potent cytotoxic C-11 modified geldanamycin analogues. Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528 [TBL] [Abstract][Full Text] [Related]
5. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives. Onuoha SC; Mukund SR; Coulstock ET; Sengerovà B; Shaw J; McLaughlin SH; Jackson SE J Mol Biol; 2007 Sep; 372(2):287-97. PubMed ID: 17662999 [TBL] [Abstract][Full Text] [Related]
6. New non-quinone geldanamycin analogs from genetically engineered Streptomyces hygroscopicus. Wu CZ; Moon AN; Jang JH; Lee D; Kang SY; Park JT; Ahn JS; Hwang BY; Kim YH; Lee HS; Hong YS J Antibiot (Tokyo); 2011 Jun; 64(6):461-3. PubMed ID: 21448187 [No Abstract] [Full Text] [Related]
7. Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition. Patel K; Piagentini M; Rascher A; Tian ZQ; Buchanan GO; Regentin R; Hu Z; Hutchinson CR; McDaniel R Chem Biol; 2004 Dec; 11(12):1625-33. PubMed ID: 15610846 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90. Le Brazidec JY; Kamal A; Busch D; Thao L; Zhang L; Timony G; Grecko R; Trent K; Lough R; Salazar T; Khan S; Burrows F; Boehm MF J Med Chem; 2004 Jul; 47(15):3865-73. PubMed ID: 15239664 [TBL] [Abstract][Full Text] [Related]
10. Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity. Zapf CW; Bloom JD; McBean JL; Dushin RG; Nittoli T; Otteng M; Ingalls C; Golas JM; Liu H; Lucas J; Boschelli F; Hu Y; Vogan E; Levin JI Bioorg Med Chem Lett; 2011 Jun; 21(11):3411-6. PubMed ID: 21515049 [TBL] [Abstract][Full Text] [Related]
11. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066 [TBL] [Abstract][Full Text] [Related]
13. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives. Kim T; Keum G; Pae AN Expert Opin Ther Pat; 2013 Aug; 23(8):919-43. PubMed ID: 23641970 [TBL] [Abstract][Full Text] [Related]
14. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Chiosis G; Caldas Lopes E; Solit D Curr Opin Investig Drugs; 2006 Jun; 7(6):534-41. PubMed ID: 16784024 [TBL] [Abstract][Full Text] [Related]
15. Geldanamycin and its anti-cancer activities. Fukuyo Y; Hunt CR; Horikoshi N Cancer Lett; 2010 Apr; 290(1):24-35. PubMed ID: 19850405 [TBL] [Abstract][Full Text] [Related]
16. The missing C-17 O-methyltransferase in geldanamycin biosynthesis. Yin M; Lu T; Zhao LX; Chen Y; Huang SX; Lohman JR; Xu LH; Jiang CL; Shen B Org Lett; 2011 Jul; 13(14):3726-9. PubMed ID: 21682254 [TBL] [Abstract][Full Text] [Related]
17. New, highly active nonbenzoquinone geldanamycin derivatives by using mutasynthesis. Eichner S; Floss HG; Sasse F; Kirschning A Chembiochem; 2009 Jul; 10(11):1801-5. PubMed ID: 19554593 [No Abstract] [Full Text] [Related]
18. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Schwock J; Pham NA; Cao MP; Hedley DW Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866 [TBL] [Abstract][Full Text] [Related]
19. Discovery of novel 17-phenylethylaminegeldanamycin derivatives as potent Hsp90 inhibitors. Li Z; Jia L; Wang J; Wu X; Shi G; Lu C; Shen Y Chem Biol Drug Des; 2015 Feb; 85(2):181-8. PubMed ID: 24903735 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of heat-shock protein 90 inhibitors: geldanamycin derivatives with broad antiviral activities. Li YP; Shan GZ; Peng ZG; Zhu JH; Meng S; Zhang T; Gao LY; Tao PZ; Gao RM; Li YH; Jiang JD; Li ZR Antivir Chem Chemother; 2010 Aug; 20(6):259-68. PubMed ID: 20710066 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]